President Trump announced a deal with Eli Lilly and Novo Nordisk to lower prices on hugely popular weight-loss drugs for Medicare, Medicaid and American patients who pay with their own money.

Mounjaro and Zepbound have helped boost the company's market cap. New data indicate these drugs do more than just help patients lose weight, contributing to potentially lowering risks to hearts ...

Novo Nordisk (NVO) and Eli Lilly & Co. (LLY) shares are trending lower in pre-market trading after President Donald Trump said the price of Ozempic, Novo’s top-selling weight-loss and diabetes ...

Shares of Eli Lilly And Co (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) are moving lower in Thursday’s after-hours session after President Donald Trump indicated that weight-loss drugs are ...

FILE PHOTO: The Eli Lilly logo is shown on one of the company's offices in San Diego, California, U.S., September 17, 2020. REUTERS/Mike Blake/File Photo FILE PHOTO: The Eli Lilly logo is ...

A Delaware federal judge dismissed a lawsuit brought by Eli Lilly, the maker of the blockbuster weight loss drugs Mounjaro and Zepbound, against a telehealth company it accused of “deceptive” ...

Eli Lilly said its investigational oral GLP-1 weight-loss drug, orforglipron, met its primary endpoints in two recent phase 3 trials. The medicine company said Wednesday the drug met the ...

FILE PHOTO: The Eli Lilly logo is shown on one of the company's offices in San Diego, California, U.S., September 17, 2020. REUTERS/Mike Blake/File Photo (Reuters) -Eli Lilly's ...

Eli Lilly (NYSE:LLY) announced on Wednesday that its oral weight loss candidate, orforglipron, reached the main goals in two Phase 3 trials for patients with type 2 diabetes, indicating its ...